Abstract

The thyroid TRK-T3 oncogene, produced by a chromosomal translocation, is a chimeric, constitutively activated version of the NTRK1/NGF receptor and it is able to transform NIH3T3 cells and differentiate PC12 cells. TRK-T3 oncoprotein triggers multiple signal transduction pathways. Among others, TRK-T3 binds and phosphorylates the Shc and SNT1/FRS2 adaptor proteins both involved in coupling the receptor tyrosine kinase to the mitogen-activated protein kinase pathway by recruiting Grb2/SOS. We were interested in defining the role of Shc in the oncogenesis by TRK-T3. The mutation of TRK-T3 tyrosine 291, docking site for both Shc and FRS2, abrogates the oncogene biological activity. To directly explore the role of Shc we used the ShcY317F mutant, which carries the mutation of a tyrosine residue involved in Grb2 recruitment. We demonstrated that the ShcY317F mutant exerts an inhibitory effect on TRK-T3 transforming activity. Such effect can be modulated by the amount of ShcY317F protein and affects the viability of cells expressing TRK-T3 by means of a mechanism involving apoptosis. Our results indicate a definitive role of the adaptor protein Shc in TRK-T3 transforming activity.

Highlights

  • The corresponding author of the above paper, Dr Angela Greco, has informed us that due to an inadvertent and minor error in the preparation of the figure, the images labelled ‘T3/Y291F’ and ‘Mock’ in Figure 2B are probably duplicates

  • Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc

  • The images are photographs of tissue culture plates related to a focus formation assay in NIH3T3 cells in which both the samples, ‘T3/Y291F’ and ‘Mock’, were scored negative

Read more

Summary

Introduction

The corresponding author of the above paper, Dr Angela Greco, has informed us that due to an inadvertent and minor error in the preparation of the figure, the images labelled ‘T3/Y291F’ and ‘Mock’ in Figure 2B are probably duplicates.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call